www.fdanews.com/articles/195971-biotronik-earns-ce-mark-for-drug-eluting-stent
![EU_Flag_pic.png](https://www.fdanews.com/ext/resources/test/Drug-Images3/EU_Flag_pic.png?t=1580334888&width=430)
Biotronik Earns CE Mark for Drug-Eluting Stent
February 21, 2020
Biotronik’s Orsiro Mission drug-eluting stent (DES) system has been granted CE Mark Certification, clearing it for marketing in Europe.
The Orsiro DES features thin struts that reduce blood flow disturbance and support the early formation of endothelial tissue, which lines the inner surface of blood vessels.
The stent system is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease caused by discrete de novo stenosis and in-stent restenosis.